Cat No.
CEI-0125
Description
GDC-0941 can inhibit p110-alpha with IC50 of less than 10 nM.
CAS No.
957054-30-7
Targets
p110-alpha
Chemical Name
2-(1H-indazol-4-yl)-6-((4-(methylsulfonyl)piperazin-1-yl)methyl)-4-morpholinothieno[3,2-d]pyrimidine
M.Wt
513.64
Purity
>99%
Solubility
DMSO 44 mg/mL Water
Storage
2 years at -20centigrade Powder
In vitro
GDC-0941, a class I selective PI3K inhibitor, can inhibit p110-alpha with IC50 of less than 10 nM. GDC-0941 showed a high efficacy of antitumor activity in two gefitinib-resistant non-small cell lung cancer (NSCLC) cell lines, A549 and H460,as H460 cells with activating mutations of PIK3CA were relatively more sensitive to GDC-0941 than A549 cells with wild-type PIK3CA.
In vivo
In GIST xenograft models, GDC-0941 causes tumor growth stabilization, inhibiting tumor cell proliferation, but did not induce apoptosis. Combination of DOX with the specific PI3K inhibitor GDC-0941 can lead to caspase 3 activation in xenografts of sarcoma cells.
